SITE014-0185

SITE014 (NLD) › SITE014-0185

SITE014-0185

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE014 (NLD) · Dr. Moreau
consented 2026-04-13

enrolled

AEs

2

Serious

1

Dropout signal

–

Adverse events

2

Grade 3 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-01-24 (study day 94); relationship: NOT RELATED; serious criteria: hospitalization

severe serious assessed

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-11-08 (study day 17); relationship: not assessed

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.